Intellia pauses Phase 3 CRISPR trial as patient develops serious liver reaction to therapy called nex-z

Intellia pauses Phase 3 CRISPR trial as patient develops serious liver reaction to therapy called nex-z

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as the company investigates and works with regulators on its CRISPR-based ATTR therapy.